Akers Biosciences has revealed the results of a study related to its BreathScan OxiCheck test, designed to determine the levels of oxidative stress in the body.
The study was carried out under the supervision of Akers Bio medical director Dr Adam Sobel in Philadelphia, US.
According to the company, the study showed a reproducibility of 100%, which means the test results from the same lung simulator had zero variation after multiple repeats.
It also demonstrated an intra-subject variation ranging from 1.61% to 14.87%, suggesting a narrow variation upon multiple repeat tests by the same human subject.
Part of the Akers Wellness platform, OxiChek is a general wellness product that will measure indicators of oxidative stress in exhaled breath.
The test can detect a broad spectrum of free radicals contained in a person's exhaled breath in just a few minutes.
OxiChek works with BreathScan Lync, a bluetooth-enabled reading device that will allow users to track their results through a mobile device.
Akers Bio co-founder and chief scientific director Dr Raymond Akers said: “Once again a study has demonstrated an exceptionally high correlation between an Akers Bio rapid breath test and an established reference laboratory blood test.”
Akers Bio CEO John Gormally said: "I am delighted with the outcome of this study. Our work in demonstrating the efficacy of the OxiChek™ test strongly underpins the commercialization strategy for this exciting new product from Akers Bio.”
Akers Bio said that BreathScan OxiChek and other health and wellness tests do not require US FDA clearance and are being marketed in the US and other territories covered by its international distribution network.